NAVERIS转发了
NAVERIS was founded on the belief that advanced diagnostics, such as NavDx, have the power to enable curative outcomes for many cancer patients with the therapies already available to us today—a premise that has been validated in clinical practice since we made our test available to physicians in 2020. I'm thrilled that the American Society for Radiation Oncology (ASTRO) has spotlighted the pivotal role of innovative biomarkers in advancing cancer medicine. Read more in the latest ASTROnews online edition about how innovative biomarkers are shaping the future of cancer care in radiation oncology.
In case you haven't seen it, the Winter edition of News from American Society for Radiation Oncology (ASTRO) features information on the role of biomarkers in radiation oncology. As a team focused on both biomarkers and improved surveillance testing for patients and HCPs in the world of HPV-driven cancers, we were very interested in what ASTRONews had to say - especially around the use of circulating tumor HPV DNA (ctHPVDNA) as a biomarker in the post-radiation treatment surveillance setting. In line with what we have seen, Dr. Riaz and Dr. Chera comment on biomarkers for head and neck cancer, specifically saying "Here, a positive ctHPVDNA test often indicates a high risk of recurrence, necessitating closer surveillance. Although not yet included in consensus guidelines, some routinely incorporate ctHPVDNA in this setting. Data suggest that recurrence can be detected in an early state with this approach." For more detail on biomarkers and surveillance approaches, visit ASTRONews to view the flipbook: https://lnkd.in/ePR22GHY #research #clinicaldata #oncology #healthcarenews